Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

GloSensor™ cAMP Assay Technical Manual

Instructions for Use of Product(s)
E1171, E1290, E1291, E2301

Literature # TM076

G-protein coupled, seven-transmembrane (7-TM) receptors (GPCRs) represent a major class of drug targets, and the prevalence of these receptors in physiologically important signaling events is well known. The GloSensor™ cAMP Assay provides an extremely sensitive and easy-to-use format for the interrogation of overexpressed or endogenous GPCRs that signal via changes in the intracellular concentration of cAMP.

The assay uses genetically encoded biosensor variants with cAMP binding domains fused to mutant forms of Photinus pyralis luciferase. Upon binding to cAMP, conformational changes occur that promote large increases in light output. Following pre-equilibration with substrate, cells transiently or stably expressing a biosensor variant can be used to assay GPCR function using a live-cell,non-lytic assay format, enabling kinetic measurements of cAMP accumulation or turnover in living cells. Moreover, the assay offers a broad dynamic range, showing up to 500-fold changes in light output. Extreme sensitivity allows detection of Gi-coupled receptor activation or inverse agonist activity in the absence of artificial stimulation by compounds such as forskolin.

Summary of Changes The following changes were made to the 1/19 version of this technical manual:

  1. Due to discontinuation of Cat.# E1261 (GloSensor™ cAMP HEK293 Cell Line), the related information in Sections 2 and 3, and all of Section 5, has been removed.
  2. A new reference 1 was added.
  3. Disclaimer statements related to Cat.# E1261 have been removed.

Printed in USA. Revised 1/19.

Experienced User Protocols